YARW

12.9009.35%
SL

Steven L. Hoerter

Executive Chairperson, CEO & President

Mr. Steven L. Hoerter, also known as Steve, is Director of Yarrow Bioscience, Inc since July 27, 2026. Mr. Hoerter is President and Chief Executive Officer of MBX Biosciences, Inc. from July 13, 2026. He was Independent Director of MBX Biosciences, Inc. from April 2025 until November 06, 2025 and serves as its Executive Chairperson since November 06, 2025. He is Independent Director of C4 Therapeutics, Inc. from November 2024. Mr. Hoerter serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He served as President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since March 18, 2019 until June 2024. He served as Independent Director at Constellation Pharmaceuticals, Inc. since September 04, 2018 until July 15, 2021. He served as the Chief Commercial Officer at Agios Pharmaceuticals, Inc since February 16, 2016 until March 15, 2019. Mr. Hoerter has global pharmaceutical and biotechnology experience. Mr. Hoerter served as Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc. since March 2015 until January 25, 2016 and served as its Senior Vice President of Commercial Operations from August 2011 to March 2015. Mr. Hoerter built and led the global commercial organization that developed go-to-market strategies for two oncology therapies. From 2010 to 2011, he served as General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. Before joining Clovis in August 2011, he was General Manager and Management Center Head at Roche, for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, he held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech's BioOncology business as Senior Director of Pipeline Development and Commercial Operations. Prior to, he held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe and Africa (11 year career). He served as Director of Deciphera Pharmaceuticals, Inc. since May 17, 2018 until June 2024. He served as Director of Ignyta, Inc. since December 8, 2016 until February 8, 2018. Mr. Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from TIAS Business School, Tilburg University and an M.S. in Management from Krannert School of Management, Purdue University.

Positions